Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Depression

In brief

The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.

Key facts

Study ID

NCT01305408

Run by

Cephalon

People needed

399

Starts

2011-03-01

Expected to finish

2013-07-01

Last updated by the study team

2016-05-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient has a diagnosis of bipolar I disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (Text Revision) (DSM-IV-TR) criteria and is currently experiencing a major depressive episode.
• Documentation that the patient has had at least 1 previous manic or mixed episode.
• The patient has had no more than 6 mood episodes in the last year.
• The patient's current major depressive episode must have started no less than 2 weeks and no more than 12 months prior to the screening visit. The current depressive episode must have begun after the patient's current mood stabilizer regime began.
• The patient must have been taking 1 (or 2) of the following protocol-allowed mood stabilizers: lithium, valproic acid, lamotrigine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone (only if taken in combination with lithium, valproic acid, or lamotrigine). The following criteria must also be met:
• The mood stabilizer(s) must have been taken a minimum 4 weeks before the onset of the major depressive episode and still be taken at the time of the screening visit at dose or blood level considered appropriate for maintenance therapy by the patient's physician.
• The patient must continue to take the same mood stabilizer(s) during the screening period; no mood stabilizer may be added during the screening period.
• The mood stabilizer(s) must be taken for a minimum of at least 8 weeks prior to the baseline visit.
• The dosage of the mood stabilizer(s) must be stable for a minimum of 4 weeks prior to the baseline visit.
• The mood stabilizer(s) must be taken in an oral formulation, with the exception of risperidone, which can be either in an oral or long-acting injection formulation.
• The patient may be taking 2 protocol-allowed mood stabilizers only if 1 of the drugs is lithium, valproic acid, or lamotrigine.

You may not qualify if…

• The patient has any Axis I disorder apart from bipolar I disorder that was the primary focus of treatment within 6 months of the screening visit or during the screening period.
• The patient has psychotic symptoms or has had psychosis within 4 weeks of the screening visit or during the screening period.
• The patient has current active suicidal ideation, is at imminent risk of self-harm, or has a history of significant suicidal ideation or suicide attempt at any time in the past that causes concern at present.
• The patient has a history of an eating disorder or obsessive compulsive disorder (OCD) within 6 months of the screening visit or during the screening period.

Where it is running

• Teva Investigational Site 295 — Sherman Oaks, California, United States
• Teva Investigational Site 122 — Temecula, California, United States
• Teva Investigational Site 606 — Jacksonville Beach, Florida, United States
• Teva Investigational Site 127 — Lauderhill, Florida, United States
• Teva Investigational Site 608 — Tampa, Florida, United States
• Teva Investigational Site 116 — Atlanta, Georgia, United States
• Teva Investigational Site 205 — Atlanta, Georgia, United States
• Teva Investigational Site 195 — Park Ridge, Illinois, United States
• Teva Investigational Site 611 — Indianapolis, Indiana, United States
• Teva Investigational Site 600 — Lafayette, Indiana, United States
• Teva Investigational Site 603 — Watertown, Massachusetts, United States
• Teva Investigational Site 207 — Brooklyn, New York, United States
• Teva Investigational Site 202 — New York, New York, United States
• Teva Investigational Site 110 — Staten Island, New York, United States
• Teva Investigational Site 411 — Staten Island, New York, United States
• Teva Investigational Site 614 — Wilmington, North Carolina, United States
• Teva Investigational Site 610 — Cincinnati, Ohio, United States
• Teva Investigational Site 615 — Toledo, Ohio, United States
• Teva Investigational Site 401 — Oklahoma City, Oklahoma, United States
• Teva Investigational Site 609 — Oklahoma City, Oklahoma, United States
• Teva Investigational Site 616 — Oklahoma City, Oklahoma, United States
• Teva Investigational Site 406 — Allentown, Pennsylvania, United States
• Teva Investigational Site 403 — DeSoto, Texas, United States
• Teva Investigational Site 612 — Friendswood, Texas, United States
• Teva Investigational Site 225 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.